All News
Filter News
Found 808,991 articles
-
QT Imaging Holdings (Nasdaq: QTI) to Ring The Nasdaq Stock Market Opening Bell
4/22/2024
QT Imaging Holdings, Inc., a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is proud to announce the Opening Bell Ceremony at the Nasdaq MarketSite in Times Square.
-
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
4/22/2024
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic and fibrotic pathways, announced it will host a virtual investor and analyst day on Friday, May 3, 2024 at 12:30 PM ET.
-
OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
4/22/2024
OraSure Technologies, Inc. has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m. ET on Wednesday, May 8, 2024.
-
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
4/22/2024
Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, announced that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 Inhibitor Suitable for Clinical Assessment”.
-
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
4/22/2024
Catalyst Pharmaceuticals, Inc. announced that it will release its first quarter 2024 financial results after the market close on Wednesday, May 8, 2024.
-
Zydus launches Mirabegron Extended-Release Tablets in the US
4/22/2024
Zydus Lifesciences Limited announces the launch of Mirabegron Extended-Release Tablets, 25 mg in the US market.
-
Amarin Announces Results of Annual General Meeting of Shareholders
4/22/2024
Amarin Corporation plc announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting.
-
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
4/22/2024
Oryzon Genomics, S.A. announced that the European Patent Office has issued an “intention to grant” communication for Oryzon’s European patent application EP18748921.6 entitled “Methods of treating behavior alterations” related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders like borderline personality disorder and schizophrenia.
-
Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital
4/22/2024
Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, announced the closing of a $40M Series A financing round.
-
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
4/22/2024
Bristol Myers Squibb and Cellares, the first Integrated Development and Manufacturing Organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments.
-
Bruker to Acquire the NanoString Business in an Asset Deal
4/22/2024
Bruker Corporation announced that it has entered into a definitive acquisition agreement with NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of solutions for spatial transcriptomics and gene expression analysis.
-
Waters Accelerates the Development of Gene-based Therapeutics with New GTxResolve Premier SEC Columns
4/22/2024
Waters Corporation introduced new GTxResolve Premier Size Exclusion Chromatography 1000Å 3-micron Columns.
-
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
4/22/2024
NovaBay® Pharmaceuticals, Inc. announces a new and enhanced marketing program that includes text message communications and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products.
-
Pancreatic Cancer Market Size to Rise at USD 7.4 Billion by 2032
4/22/2024
The pancreatic cancer market size grew to USD 2.05 billion in 2022 and is estimated to hit approximately USD 7.4 billion by 2032, with a CAGR of 13.7% for the period of 2023 – 2032.
-
Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials
4/22/2024
Kraig Biocraft Laboratories, Inc., announces what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial.
-
Primary Cell Culture Market Size to Worth Around USD 21.51 Billion by 2033
4/22/2024
According to Precedence Research, the primary cell culture market size was valued at USD 7.03 billion in 2023 and is expected to be worth around USD 21.51 billion by 2033, expanding at a CAGR of 11.81% from 2024 to 2033.
-
Single-cell Omics Market to Attain Valuation US$ 35.11 billion by 2033
4/22/2024
The global single-cell omics market size was evaluated at US$ 4.16 billion in 2023 and is expected to attain around US$ 35.11 billion by 2033, growing at a CAGR of 23.96% from 2024 to 2033.
-
High Potency Active Pharmaceutical Ingredients Market Size, Growth, Report 2024-2033
4/22/2024
According to Vision Research Reports, the global high potency active pharmaceutical ingredients market size was valued at USD 26.75 billion in 2023 and it is expected to surpass around USD 49 billion by 2033 with a CAGR of 6.24% from 2024 to 2033.
-
BoomRay's Radioactive Diagnostic New Drug [18F]BF3-BPA Injection Completes First Subject Enrollment in Phase I Clinical Trial
4/22/2024
BoomRay Pharmaceutical Co., Ltd. (“BoomRay”) announced that the phase I clinical trial of its positron emission tomography (PET) tracer [18F]BF3-BPA injection for the diagnosis of primary and metastatic brain tumors has completed the enrollment of the first subject.
-
Cell Therapy Market Size to Grow At 22.67% CAGR Till 2033
4/22/2024
The global cell therapy market size was valued at USD 4.85 billion in 2023 and is projected to surpass around USD 37.42 billion by 2033, registering a CAGR of 22.67% over the forecast period of 2024 to 2033 according to Nova One Advisor.